Zacks Investment Research upgraded shares of ReNeuron (OTCMKTS:RNUGF) from a hold rating to a buy rating in a research note published on Thursday morning. Zacks Investment Research currently has $1.50 target price on the stock.

According to Zacks, “ReNeuron Group plc is involved in the development of cell-based therapies. Its therapeutic candidate is CTX stem cell therapy for the treatment of patients left disabled by the effects of a stroke which are in clinical development phase. ReNeuron Group plc is headquartered in Pencoed, the United Kingdom. “

How to Become a New Pot Stock Millionaire

Shares of ReNeuron stock traded up $1.33 during mid-day trading on Thursday, reaching $1.35. The company had a trading volume of 1,000 shares, compared to its average volume of 5,500. ReNeuron has a 1 year low of $0.02 and a 1 year high of $1.35.

COPYRIGHT VIOLATION WARNING: “ReNeuron (RNUGF) Upgraded by Zacks Investment Research to Buy” was first posted by Watch List News and is the property of of Watch List News. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. & international copyright and trademark laws. The legal version of this news story can be read at https://www.watchlistnews.com/reneuron-rnugf-upgraded-by-zacks-investment-research-to-buy/1960148.html.

ReNeuron Company Profile

ReNeuron Group plc develops and sells cell-based therapies in the United Kingdom. The company's lead therapeutic candidate is CTX stem cell therapy, which has been completed Phase III clinical trial for the treatment of patients left disabled by the effects of a stroke, as well as that has been completed Phase I clinical trial to treat critical limb ischaemia, a side effect of diabetes.

Receive News & Ratings for ReNeuron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ReNeuron and related companies with MarketBeat.com's FREE daily email newsletter.